PTC Therapeutics PTCT announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.
Earnings and Revenue
PTC Therapeutics' per-share loss will be near 14 cents per share on sales of $74.4 million, according to Wall Street analysts.
PTC Therapeutics' loss in the same period a year ago was 78 cents per share. Quarterly sales came in at $25.19 million. If the company were to post earnings inline with the consensus estimate when it reports Tuesday, EPS would be up 82.05 percent. Revenue would be up 195.34 percent from the year-ago period.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.47 | -1.3 | -1.03 | -1.08 |
| EPS Actual | -0.82 | -0.44 | -0.85 | -0.78 |
Stock Performance
For a full 12 months, the return has risen by 143.19 percent. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The popular rating by analysts on PTC Therapeutics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
PTC Therapeutics is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
